Compare

Immunocore/$IMCR

1D1W1M3M6MYTD1Y5YMAX

About Immunocore

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Ticker
$IMCR
Sector
Health
Primary listing
NASDAQ
Employees
524
Headquarters
Abingdon, United Kingdom
Website
www.immunocore.com

Immunocore Metrics

BasicAdvanced
$1.6B
-
-$0.63
0.81
-

What the Analysts think about Immunocore

Analyst ratings (Buy, Hold, Sell) for Immunocore stock.
Analyst projections of the future price of Immunocore stock.

Bulls say / Bears say

KIMMTRAK remains a growing commercial base: nine-month sales rose 10% year on year to $324.8 million, with growth across the US, Europe and international markets. The company says underlying Q3 growth was about 10% after adjusting for stocking and calendar effects. (Immunocore)
Five-year trial follow-up strengthens KIMMTRAK’s case: overall survival was 16% against 8% in the control arm, with a hazard ratio of 0.67. Durable survival evidence may help support its use and commercial position. (Immunocore)
Brenetafusp plus KIMMTRAK showed an encouraging early signal in metastatic uveal melanoma, including a 70% two-year survival rate among 17 evaluable first-line patients. Immunocore plans a randomised Phase 2/3 trial, creating a potential route to extend its reach in this cancer. (Immunocore)
Revenue remains highly dependent on KIMMTRAK, leaving the business exposed to any loss of demand or market share. Management also said a first competitor in uveal melanoma may arrive within the coming year. (Immunocore, Investing.com)
Reported Q3 sales slipped 1.4% year on year to $102.2 million, while the net loss widened to $14.2 million from $0.2 million a year earlier. The company attributed the sales comparison partly to timing effects, but its rising R&D costs and quarterly loss show the pressure to sustain commercial growth while funding trials. (Immunocore)
Pipeline expansion is not yet proven: the encouraging brenetafusp-plus-KIMMTRAK survival result came from only 17 evaluable first-line patients. A separate Phase 3 trial’s overall-survival results are not expected until Q2 2027, leaving a long wait for pivotal evidence. (Immunocore, Immunocore)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

Immunocore Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

Immunocore Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing Immunocore

Funds
Fund name
Fund size
$IMCR weighting
iShares Nasdaq US Biotechnology£BTEK
$1.3B0.09%
iShares Nasdaq US Biotechnology$BTEC
$1.3B0.09%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.